title: The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients.
abstract: OBJECTIVE
  The objective of this study was to examine the effects of angiotensin-converting enzyme inhibitors on peritoneal membrane transport, peritoneal protein loss, and proteinuria in peritoneal dialysis patients.
  
  
  METHODS
  Fifty-four peritoneal dialysis patients were included in the study. The patients were divided into two groups. Group 1 (n = 34) was treated with angiotensin-converting enzyme inhibitors. Group 2 (n = 20) did not receive any antihypertensive drugs during the entire follow-up. Eleven patients were excluded from the study thereafter. Thus, a total of 30 patients in Group 1 and 13 patients in Group 2 completed the study. We observed the patients for six months. Group 1 patients received maximal doses of angiotensin-converting enzyme inhibitors for six months. Parameters at the beginning of study and at the end of six months were evaluated.
  
  
  RESULTS
  At the end of six months, total peritoneal protein loss in 24-hour dialysate effluent was significantly decreased in Group 1, whereas it was increased in Group 2. Compared to the baseline level, peritoneal albumin loss in 24-hour dialysate effluent and 4-hour D/P creatinine were significantly increased in Group 2 but were not significantly changed in Group 1. A covariance analysis between the groups revealed a significant difference only in the decreased amount of total protein loss in 24-hour dialysate. Proteinuria was decreased significantly in Group 1.
  
  
  CONCLUSIONS
  This study suggests that angiotensin-converting enzyme inhibitors reduce peritoneal protein loss and small-solute transport and effectively protect peritoneal membrane transport in peritoneal dialysis patients.
authors.affiliation: Department of Nephrology, Sisli Etfal Research and Education Hospital, Istanbul, Turkey. tanerbast@yahoo.com
authors.forename: Taner
authors.initials: T
authors.lastname: Basturk
authors.forename: Abdulkadir
authors.initials: A
authors.lastname: Unsal
authors.forename: Yener
authors.initials: Y
authors.lastname: Koc
authors.forename: Eren
authors.initials: E
authors.lastname: Nezaket
authors.forename: Elbis
authors.initials: E
authors.lastname: Ahbap
authors.forename: Tamer
authors.initials: T
authors.lastname: Sakaci
authors.forename: Mustafa
authors.initials: M
authors.lastname: Sevinc
mesh_terms: D000293:Adolescent; D000328:Adult; D000418:Albumins / Q000032:analysis / Q000378:metabolism*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D001692:Biological Transport; D004812:Epidemiologic Methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D010537:Peritoneum / Q000378:metabolism*; D011506:Proteins / Q000378:metabolism; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000418:Albumins; D000806:Angiotensin-Converting Enzyme Inhibitors; D011506:Proteins